Corcept Therapeutics (CORT) Misses Q4 EPS by 12c, provides guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $114.10 -0.66%
Revenue Growth %: +54.6%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +54.6%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.26, $0.12 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $181.89 million versus the consensus estimate of $198.05 million.
GUIDANCE:
Corcept Therapeutics sees FY2025 revenue of $900-950 million, versus the consensus of $855.1 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades Nucor (NUE) to Hold, 'Guides Conservative Earnings Yet Again'
- NASA awards SpaceX $946M for three more ISS crew missions
- Popular stocks with increasing option volume: MSTR SPCX MU INTC HOOD NFLX COIN AVGO PLTR SNDK ORCL
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
